Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena

Affiliations

Editorial

Leonard J Appleman. J Natl Cancer Inst. 2021.

. 2021 Jan 4;113(1):7-8.

doi: 10.1093/jnci/djaa077.

¹ Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

No abstract available

Comment on

Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
Bandini M, Ross JS, Raggi D, Gallina A, Colecchia M, Lucianò R, Giannatempo P, Farè E, Pederzoli F, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Deho' F, Ali SM, Madison R, Chung JH, Salonia A, Briganti A, Montorsi F, Necchi A. Bandini M, et al. J Natl Cancer Inst. 2021 Jan 4;113(1):48-53. doi: 10.1093/jnci/djaa076. J Natl Cancer Inst. 2021. PMID: 32516377 Free PMC article. Clinical Trial.

1. Necchi A, Anichini A, Raggi D, et al.Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36(6_suppl):TPS534. - PubMed
1. Grossman HB, Natale RB, Tangen CM, et al.Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866. - PubMed
1. Bandini M, Ross J, Raggi D, et al.Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer. J Natl Cancer Inst. 2021;113(1):48–53. - PMC - PubMed
1. Yoneda K, Imanishi N, Ichiki Y, et al.Treatment of non-small cell lung cancer with EGFR-mutations. J UOEH. 2019;41(2):153–163. - PubMed
1. Pernas S, Tolaney SM.. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;11:175883591983351. - PMC - PubMed